The team that decided your dog deserves the same cancer medicine you would get - and built the data to deliver it.
In an exam room somewhere in America, a veterinarian swabs a tumor and drops the sample in a prepaid box. A few weeks later a report comes back - not a vague stage and a shrug, but a list of the exact mutations driving that one dog's cancer, paired with targeted drugs matched to them. That report is the product of One Health Company, the business most people know by its consumer name, FidoCure.
It is a strange thing to build. Human precision oncology is a multi-billion-dollar field. Veterinary medicine, for the most part, still treats cancer the way oncology did decades ago: surgery, broad chemotherapy, and hope. One Health Company looked at that gap and asked an uncomfortable question - why should a dog get worse cancer care than its owner, when the two diseases are, genetically, often the same illness?
Cancer is the leading cause of death in dogs over the age of two. Anyone who has owned an older dog knows the script: a lump, a biopsy, a referral, and a conversation about comfort. The tools that have transformed human oncology - genomic sequencing, biomarker-driven targeted therapy, real-world evidence - rarely make it to the animal hospital. Not because the science doesn't apply, but because nobody had built the pipes.
Here is the part that makes it interesting rather than merely sad. Dogs get cancer spontaneously, living in the same homes and breathing the same air as the humans who love them. Their tumors carry many of the same mutation hotspots found in human cancers. That makes the family dog one of the better natural models of human disease we have - far closer to the real thing than a mouse engineered in a lab. The problem and the opportunity, conveniently, turned out to be the same animal.
Caption: The most ambitious cancer-research subject of the decade may be asleep on your couch right now.
One Health Company was founded in 2016 by Christina Lopes and Benjamin Lewis. Lopes, the CEO, had spent time caring for her father through terminal lung cancer - she had seen what modern oncology can do, and what it cannot. Lewis, a former elite kayaker who had brushed against cutting-edge sports medicine, went looking for genomics-informed treatment when his own dog was diagnosed with cancer, and found that it essentially did not exist for animals.
The bet was not modest. They would have to sequence tumors, build a database that did not yet exist, win over veterinarians trained on conventional protocols, and convince investors that precision medicine for dogs was a real market and not a charming hobby. Andreessen Horowitz and Y Combinator backed them early. Plenty of people, presumably, thought it was a long shot. The long shot is now in roughly 1,350 clinics.
Shaped by caring for her father through terminal lung cancer, she now leads the fight against the same disease in dogs - and, by extension, the data that could help humans too.
A former Olympic-level kayaker whose own dog's diagnosis sent him hunting for precision treatment that wasn't there - so he helped build it.
Caption: One founder learned from a hospital, the other from a finish line. Both ended up at the vet.
FidoCure runs on a loop that is simple to describe and hard to build. A vet sends in a tumor sample. The company's CLIA-certified lab sequences it and identifies the cancer-driving mutations. An AI layer cross-references those mutations against treatment data and recommends targeted, often FDA-approved therapies, which the veterinarian prescribes through pharmacy partners. Then - and this is the part competitors can't copy - every outcome flows back into the dataset, making the next recommendation a little sharper.
Next-generation sequencing of a dog's tumor to find the mutations actually driving the cancer.
Launched 2025. Reads real-world evidence from thousands of treated cases to optimize therapy recommendations.
Mutation-matched, biomarker-driven treatments - backed by an industry-first patent and a growing pipeline.
Christina Lopes and Benjamin Lewis set out to bring precision oncology to dogs under the FidoCure brand.
Backed early by Andreessen Horowitz and Y Combinator; the platform begins reaching veterinarians nationwide.
Led by Polaris Partners and Borealis Ventures, with a16z, Lerer Hippeau, Y Combinator and Tau Ventures - to widen access.
The USPTO grants a patent for AI-driven drug development and a novel targeted therapy/biomarker for canine cancer.
An AI engine analyzing real-world evidence from ~6,000 dogs to optimize cancer therapies - the dataset turned into a product.
It is easy to say "AI-driven precision medicine." It is harder to back it with a dataset nobody else has. One Health Company's edge is not a clever model alone - it is the volume of real, structured canine cancer data feeding it, gathered across a clinic network that keeps growing.
Bars are scaled for readability, not to a common axis - the point is the shape of the moat, not the arithmetic.
Caption: A database is a boring thing to photograph and a very hard thing to compete with.
Research collaboration on canine cancer genomics, with MIT and Harvard's flagship genomics center.
Academic collaboration in veterinary oncology research.
Findings published in journals including Nature - science, not just marketing.
The investor list reads like people who recognized that this is a data company in a veterinary coat. The same names that fund human-health platforms wrote checks here, betting that the canine dataset is valuable on its own terms - and possibly a shortcut to insights that matter on both ends of the leash.
The company's name comes from the One Health concept: the notion that human, animal and environmental health are knotted together. Treat the dog well and you generate evidence that could, eventually, help the human. That is the long arc here - not just better outcomes for pets, but a comparative-oncology data asset that makes cancer drug development faster and cheaper for everyone with a pulse.
For now, the practical promise is narrower and, frankly, more moving: a vet who can offer a frightened owner something other than a shrug, and a dog that gets a few more good seasons because someone read its cancer instead of guessing at it.
Return to that prepaid box on the vet's counter. A decade ago it would have been unthinkable - the idea that a general-practice clinic in any of the fifty states could order a genomic workup for a dog and get back a mutation-matched treatment plan. Today it is a logo on an intake form. That is what One Health Company actually changed: not the biology of cancer, but who gets access to the best tools against it.
The harder bet is still playing out. Eight pending patents, an AI engine learning from every new case, a dataset growing faster than competitors can assemble one. If comparative oncology works the way the founders think it does, the dog on the exam table isn't just a patient. It's a clue. And the company that decided dogs deserved real cancer medicine may turn out to have been quietly working on ours all along.